TCG Crossover raises $600m for debut Asian biotech fund, opens Shanghai and Hong Kong offices
Friday, October 9, 2026 · first reported by AltAssets
TCG Crossover has closed its first fund dedicated to Asian life sciences, raising $600m. The fund extends the firm's strategy beyond the US and Europe, where it already invests, and gives it more exposure to biotechnology across Asia. The firm is also opening offices in Shanghai and Hong Kong.
- Firm
- TCG Crossover
- Fund
- TCG Crossover Asian Life Sciences Fund I
- Size
- $600M
- Stage
- Launch
- Asset class
- Venture
- Geography
- Asia-Pacific
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Phoenix Venture Partners closes debut fund at $23M, eyes 20-company portfolioDealroom
- Nicola Forrest anchors Antler’s $70 million 3rd fund in $30m push for women foundersStartup Daily
- Khazanah, InvestPenang launch $24.5M fund for Penang chip startupsDealroom
- Protego Ventures Closes $125 Million Fund I For Israeli Defense TechnologyPulse 2.0
- Spectrum Equity raises record $2.5bn flagship fund, 25% larger than predecessorAltAssets +3
- Dallas VC firm Disruptive is targeting a $10 billion megafund after Groq bets pay offQuartz